July 31, 2019

In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


  1. January 10, 2024

    Union Funds Exit Amgen, Teva Antitrust MDL

    Teva Pharmaceuticals has settled its differences with the union funds making up the indirect purchase class in multidistrict litigation accusing it of hatching an illegal deal to remove a generic calcium-control drug from the market.

4 other articles on this case. View all »


Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!